Subscribe

Stay Informed. Stay Ahead.

Subscribe to receive curated updates, expert insights, and practical education—delivered straight to your inbox.

Get timely coverage on new approvals, case-based discussions, conference highlights, and practical tools for everyday practice in community oncology and hematology.

Subscribe
*
Skip to main content
OncUpdates
  • Conferences
    • ESMO
    • WCLC
    • ASCO
  • Videos & Podcasts
    • Challenging Cases
      • Hematology
      • Lung Cancer
    • New Approvals
      • GI
      • GU
      • Lung Cancer
    • Tox Check
      • GI
      • GU
      • Lung Cancer
      • Breast Cancer
    • Treatment Algorithms
      • Hematology
      • Lung Cancer
      • Ovarian Cancer
  • Articles
    • Breast Cancer
    • GU Oncology
    • GI Oncology
    • Hematology
    • Lung Cancer
      • NSCLC
      • SCLC
  • Clinical Insights
    • Bladder Cancer
    • Lung Cancer
      • SCLC
      • NSCLC
  • Conferences
    • ESMO
    • WCLC
    • ASCO
  • Videos & Podcasts
    • Challenging Cases
      • Hematology
      • Lung Cancer
    • New Approvals
      • GI
      • GU
      • Lung Cancer
    • Tox Check
      • GI
      • GU
      • Lung Cancer
      • Breast Cancer
    • Treatment Algorithms
      • Hematology
      • Lung Cancer
      • Ovarian Cancer
  • Articles
    • Breast Cancer
    • GU Oncology
    • GI Oncology
    • Hematology
    • Lung Cancer
      • NSCLC
      • SCLC
  • Clinical Insights
    • Bladder Cancer
    • Lung Cancer
      • SCLC
      • NSCLC

Explore Videos, Articles & More

SCLC

Home / Clinical Insights / Lung Cancer / SCLC
Key Takeaways From IMforte for Clinicians Treating ES-SCLC
Key Takeaways From IMforte for Clinicians Treating ES-SCLC

Ticiana Leal, MD, Stephen Liu, MD, Isabel Preeshagul, DO, MBS, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Sequencing Lurbinectedin in ES-SCLC with CNS Involvement
Sequencing Lurbinectedin in ES-SCLC with CNS Involvement

Ticiana Leal, MD, Stephen Liu, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Managing Lurbinectedin Adverse Events in ES-SCLC Maintenance Therapy
Managing Lurbinectedin Adverse Events in ES-SCLC Maintenance Therapy

Isabel Preeshagul, DO, MBS, Stephen Liu, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Clinical Relevance of IMforte Survival Data in ES-SCLC
Clinical Relevance of IMforte Survival Data in ES-SCLC

Ticiana Leal, MD, Stephen Liu, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Efficacy Outcomes in the IMforte Trial: PFS, OS, and Clinical Impact
Efficacy Outcomes in the IMforte Trial: PFS, OS, and Clinical Impact

Stephen Liu, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

IMforte Study Design and Maintenance Approach in ES-SCLC
IMforte Study Design and Maintenance Approach in ES-SCLC

Isabel Preeshagul, DO, MBS, Rahul Gosain, MD, MBA, Rohit Gosain, MD

IMforte: Maintenance With Lurbinectedin in Newly Diagnosed ES-SCLC
IMforte: Maintenance With Lurbinectedin in Newly Diagnosed ES-SCLC

Rohit Gosain, MD, Rahul Gosain, MD, MBA, Stephen Liu, MD, Ticiana Leal, MD, Isabel Preeshagul, DO, MBS

OncUpdates

Empowering oncology professionals with The latest insights, breakthroughs, And expert opinions

Quick Links

  • About Us
  • Contact Us
  • Follow on X
  • Follow on LinkedIn

Legal

  • Terms of Use
  • Privacy Policy
  • Cookie Settings

Subscribe to Our Newsletters


Property of SignifyMD LLC, All Rights Reserved 2025 SignifyMD LLC PO Box 512, Brielle, NJ 08730


Oncology Resources | Hematology Support | Community Oncology